AI in Healthcare
Jun 20, 2026
Resumo do dia
AI Rewrites Drug Discovery: Eli Lilly and Twist Bioscience Chart Two Distinct Industrialization Paths. The Next Wave of Medical AI Could Mint More Millionaires Than the First -- Here Are the Stocks to Own. Merck, Protillion Launch AI Drug Discovery Collaboration with Up-to-$510M in Milestone Payments
Principais notícias
- 1
AI Rewrites Drug Discovery: Eli Lilly and Twist Bioscience Chart Two Distinct Industrialization Paths
AI Rewrites Drug Discovery: Eli Lilly and Twist Bioscience Chart Two Distinct Industrialization Paths
- 2
The Next Wave of Medical AI Could Mint More Millionaires Than the First -- Here Are the Stocks to Own
The Next Wave of Medical AI Could Mint More Millionaires Than the First -- Here Are the Stocks to Own
- 3
Merck, Protillion Launch AI Drug Discovery Collaboration with Up-to-$510M in Milestone Payments
Merck, Protillion Launch AI Drug Discovery Collaboration with Up-to-$510M in Milestone Payments
- 4
Pramaana Labs raises $27M seed round from Khosla Ventures to bring formal verification to AI
Pramaana Labs raises $27M seed round from Khosla Ventures to bring formal verification to AI
- 5
New research shows how AMIE, our medical AI, could help manage health conditions
New research shows how AMIE, our medical AI, could help manage health conditions
- 6
Merck and Protillion ink AI drug discovery deal worth up to $510M
Merck and Protillion ink AI drug discovery deal worth up to $510M
Fontes
- AI Rewrites Drug Discovery: Eli Lilly and Twist Bioscience Chart Two Distinct Industrialization Paths
- The Next Wave of Medical AI Could Mint More Millionaires Than the First -- Here Are the Stocks to Own
- Merck, Protillion Launch AI Drug Discovery Collaboration with Up-to-$510M in Milestone Payments
- Pramaana Labs raises $27M seed round from Khosla Ventures to bring formal verification to AI
- New research shows how AMIE, our medical AI, could help manage health conditions
- Merck and Protillion ink AI drug discovery deal worth up to $510M
- Protillion and Merck & Co sign AI drug discovery pact
- General-purpose LLMs outperform specialized clinical AI tools
- Pfizer signs licence agreement with Chai for AI drug discovery
- AI Agent Failure Detection and Root Cause Analysis with Strands Evals
Share this with a friend
Send today's roundup to anyone who wants to keep up.
Get daily AI news free with AIToday
200+ AI sources, summarized in 1 minute. Email / LINE / Slack.
Sign up free